Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

THTX

Theratechnologies (THTX)

Theratechnologies Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:THTX
DateTimeSourceHeadlineSymbolCompany
02/26/20258:32AMEdgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:THTXTheratechnologies Inc
02/26/20258:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
02/26/20257:30AMGlobeNewswire Inc.Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024NASDAQ:THTXTheratechnologies Inc
02/21/20254:37PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
02/14/202511:12AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
02/14/202510:51AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
02/14/20257:30AMGlobeNewswire Inc.Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business UpdateNASDAQ:THTXTheratechnologies Inc
02/13/20257:45PMGlobeNewswire Inc.Theratechnologies Resumes Distribution of EGRIFTA SV®NASDAQ:THTXTheratechnologies Inc
01/10/20257:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
01/09/20255:05PMGlobeNewswire Inc.Theratechnologies Provides Update on EGRIFTA SV® SupplyNASDAQ:THTXTheratechnologies Inc
12/19/20243:55PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
12/18/20241:30PMGlobeNewswire Inc.Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing EnvironmentNASDAQ:THTXTheratechnologies Inc
12/12/202411:58AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
12/10/20243:15PMGlobeNewswire Inc.Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLANASDAQ:THTXTheratechnologies Inc
12/09/20242:35PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
12/09/20247:30AMGlobeNewswire Inc.Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian CancerNASDAQ:THTXTheratechnologies Inc
12/05/202410:43AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
12/04/202411:44AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
12/04/20248:53AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
12/04/20247:30AMGlobeNewswire Inc.Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in CanadaNASDAQ:THTXTheratechnologies Inc
12/03/20244:30PMGlobeNewswire Inc.Theratechnologies Announces Resumed Production of EGRIFTA SV®NASDAQ:THTXTheratechnologies Inc
12/02/202410:20AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
12/02/20247:30AMGlobeNewswire Inc.Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement QuébecNASDAQ:THTXTheratechnologies Inc
11/26/202411:41AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
11/26/20247:30AMGlobeNewswire Inc.Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA ReviewNASDAQ:THTXTheratechnologies Inc
10/17/20242:00PMGlobeNewswire Inc.Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIVNASDAQ:THTXTheratechnologies Inc
10/17/20247:30AMGlobeNewswire Inc.Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug ResistanceNASDAQ:THTXTheratechnologies Inc
10/10/20248:36AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
10/10/20248:31AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:THTXTheratechnologies Inc
10/10/20247:30AMGlobeNewswire Inc.Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024NASDAQ:THTXTheratechnologies Inc
 Showing the most relevant articles for your search:NASDAQ:THTX

Your Recent History

Delayed Upgrade Clock